Company Overview - ProQR Therapeutics N.V. is focused on developing transformative RNA therapies using its proprietary Axiomer™ RNA editing technology platform [1][4] - The company aims to create a new class of medicines targeting both rare and prevalent diseases with unmet medical needs [4] Axiomer™ Technology - Axiomer™ is a next-generation RNA base editing technology that allows for specific single nucleotide changes in RNA [3][4] - The technology utilizes the human cell's own ADAR (Adenosine Deaminase Acting on RNA) machinery to convert Adenosine (A) to Inosine (I), which is then translated as Guanosine (G), effectively correcting disease-causing mutations [3] Upcoming Events - ProQR will hold its Annual General Meeting (AGM) on June 3, 2025, at 15:30 CEST in Amsterdam, Netherlands [1] - Relevant documents for the AGM will be available on ProQR's website and the SEC's website [2]

Core Insights - ProQR Therapeutics has appointed Dennis Hom as Chief Financial Officer and Dr. Cristina Lopez Lopez as Chief Medical Officer to advance its Axiomer platform and RNA editing programs into clinical stages [1][2][3] Leadership Appointments - Dennis Hom brings over 25 years of financial leadership experience, having raised more than $4.5 billion in capital and executed transactions totaling over $57 billion in disclosed value [2] - Dr. Cristina Lopez Lopez has over 20 years of experience in translational R&D, previously serving as Global Head of Neurodegeneration at Johnson & Johnson and holding senior roles at Roche and Novartis [3] Transition of Current Executives - Current CFO Jurriaan Dekkers and Chief Corporate Development Officer René Beukema will step down but remain during a transitional period to ensure continuity [4][5] Axiomer Technology Overview - ProQR is pioneering Axiomer™, a next-generation RNA base editing technology that allows specific single nucleotide edits in RNA, potentially leading to new medicines for various diseases [5][7] - Axiomer™ Editing Oligonucleotides (EONs) utilize the human cell's ADAR machinery to correct disease-causing mutations in RNA, modulating protein expression or altering protein functions [5]